Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

Conference Correspondent  - Conference Correspondent, ASH

Chari and colleagues presented results of a 4-arm, open-label, multicenter, phase 1b study that evaluated the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab in combination with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.1 The study population (n = 98) had received a median of 4.0 (2-13) prior therapies; 98% of patients were refractory to bortezomib, 32% to carfilzomib, 89% to lenalidomide, and 67% to both a proteasome inhibitor and immunomodulatory drug. Of the 38 patients who discontinued study treatment, 19 (50%) were due to progressive disease and 8 (21%) were due to adverse events (AEs). Daratumumab-specific infusion-related reactions occurred in 52 patients, and included chills (14%), cough (11%), and dyspnea (11%). Grade 3/4 AEs were mostly hematologic, including neutropenia, anemia, leukopenia, and thrombocytopenia; nonhematologic grade 3/4 AEs included dyspnea, hypertension, and fatigue. Seventeen deaths were reported. In the 75 patients who had >1 postbaseline assessments, an overall response rate (ORR) of 53% was achieved, including 4 stringent complete responses, 3 complete responses, 25 very good partial responses, and 21 partial responses. Patients also achieved greater depth of response over time. In the cohort of patients with double-refractory disease, an ORR of 67% was achieved. The 6-month progression-free survival was 66%. Based on these results, the authors concluded that the addition of daratumumab to Pom/Dex resulted in high response rates, greater depth of responses, without unexpected or exacerbating known toxicities.

  1. Chari A, et al. ASH 2015. Abstract 508.
Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: April 27, 2020